Effect of Systemic and Local Ozone Therapy in Lipedema

NCT ID: NCT06954870

Last Updated: 2025-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-25

Study Completion Date

2025-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lipedema is a disease characterized by enlargement of the subcutaneous tissue and is observed only in the female population. Recently, the inflammatory cascade has been suggested to be the initiator of lipoedema and to play a role in its progression. The presence of pain in the involved areas is the most important symptom affecting the patient's QoL.

In the literature, ozone therapy is used both locally and systemically in many diseases in which inflammation is involved in the etiopathogenesis. There are many studies on plantar fasciitis, lateral epicondylitis, rheumatoid arthritis, osteoarthritis, etc. In addition to its anti-inflammatory properties, ozone therapy, which has analgesic and aseptic properties, has not been found in the literature in patients with lipedema.

The aim of this study was to investigate the effect of ozone therapy on pain symptoms and subcutaneous tissue thickness in patients with lipedema and to compare local and systemic ozone applications in these patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study, which is planned as a prospective randomized intervention, will include 50 female patients aged 18-65 years with a diagnosis of lipedema by a physician who applied to Etlik City Hospital Physical Medicine and Rehabilitation clinic and had pain \>4 evaluated by VAS.

Since there is no study evaluating ozone therapy in lipedema in the literature, the sample size calculated with G\*Power 3.0.10a based on another ozone therapy study was found to be 15 patients each. Considering the possibility of dropout from the study, the sample size was determined as 50 volunteers in total.

After clinical diagnosis, pain with visual analog scale (VAS) and pain detect pain questionnaire will be applied to evaluate neuropathic pain. In patients with lipedema, measurements will be made by a physical medicine and rehabilitation physician with 10 years of experience in musculoskeletal ultrasonography from the areas previously defined ultrasonographically in the literature (Midpoint between the superior anterior iliac crest and the inferior patellar border, medial tubercle of the femur, midpoint between the tibial tuberosity and the medial malleolus, midpoint between the lateral malleolus and the fibular head, medial supramalleolar) with the ultrasonography device available in the clinic.Patients' age, comorbidities, medications and routine laboratory parameters such as neutrophil/lymphocyte ratio, platelet distribution width, mean platelet volume, sedimentation, CRP, hemogram values will be recorded. VAS, pain detection and ultrasonographic measurements will be repeated at the 1st and 3rd month after the end of the application.

After the patients were randomized into three groups, the first group will receive local ozone, the second group will receive systemic ozone, and the third group will receive both local and systemic ozone. Local ozone will be injected into the painful points of the patient at the level of the medial tubercle of the femur, 10 gamma 10 cc ozone injection will be made radiationally from 5 regions with 1 cm intervals under the guidance of USG (3 sessions). Systemic ozone application will be given in 3 sessions of 40 gamma each.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lipedema Pain Activities of Daily Living Musculoskeletal Ultrasound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Systemic ozone therapy

1 session of 40 gamma per week, a total of three weeks of major ozone therapy will be applied

Group Type EXPERIMENTAL

Ozone therapy

Intervention Type OTHER

As detailed in the research arms, major ozone application and local ozone application will be performed.

Local ozone therapy

10 gamma local ozone injection per week, a total of three weeks will be performed 5 times with 1 cm intervals to the painful points of the patient.

Group Type EXPERIMENTAL

Ozone therapy

Intervention Type OTHER

As detailed in the research arms, major ozone application and local ozone application will be performed.

Both systemic and local ozone therapy

1 session of 40 gamma per week, a total of three weeks of major ozone therapy will be applied and also 10 gamma local ozone injection per week, a total of three weeks will be performed 5 times with 1 cm intervals to the painful points of the patient.

Group Type EXPERIMENTAL

Ozone therapy

Intervention Type OTHER

As detailed in the research arms, major ozone application and local ozone application will be performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ozone therapy

As detailed in the research arms, major ozone application and local ozone application will be performed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To have been diagnosed with clinical lipedema.
* Pain assessed by VAS of 5 or more
* Being a woman
* Being between 18-65 years old

Exclusion Criteria

* Presence of venous insufficiency leading to subcutaneous changes
* Having diseases that may cause edema
* Use of painkillers (NSAIDs/Opioids) up to 1 week before the injection
* Open wound or infection at the site of infection
* Bleeding disorders or use of anticoagulant, antiplatelet drugs uncontrolled systemic disease
* G6PD deficiency
* Cases where the pain cannot be explained by lipoedematous tissue
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara Etlik City Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Başak Mansız-Kaplan

Assoc. Prof. Dr. Başak Mansız Kaplan Ankara Etlik City Hospital, Department of Physical Medicine and Rehabilitation, Head of the Orthopedic Rehabilitation Clinic

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Başak Mansız Kaplan, MD,AssocProf

Role: PRINCIPAL_INVESTIGATOR

Ankara Etlik City Hospital, Department of Physical Medicine and Rehabilitation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ankara Etlik City Hospital, Department of Physical Medicine and Rehabilitation

Ankara, , Turkey (Türkiye)

Site Status ACTIVE_NOT_RECRUITING

Ankara Etlik City Hospital, Department of Physical Medicine and Rehabilitation

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Başak Mansız Kaplan, MD,AssocProf

Role: CONTACT

+905358582176

Ayşegül Yaman, MD

Role: CONTACT

+905052423917

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ayşegül Yaman, MD

Role: primary

+905052423917

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025/16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Shockwave Therapy (SWT)
NCT03986983 COMPLETED NA
Pilot Study on the Submental Area
NCT01859091 COMPLETED NA